ALLERGIC REACTION UPON INTRAVITREAL ADMINISTRATION OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS
- Resource Type
- Academic Journal
- Authors
- Meredith, Gavin G.; Schkade, Paul A.; Joondeph, Brian C.
- Source
- Retinal Cases & Brief Reports. Jun 15, 2019 13(3):287-289
- Subject
- Language
- English
- ISSN
- 1935-1089
PURPOSE:: To describe the patientʼs allergic response to anti–vascular endothelial growth factor drugs after receiving intravitreal bevacizumab for choroidal neovascularization. METHODS:: Clinical case report. RESULTS:: Formal allergy evaluation revealed hypersensitivity to bevacizumab and ranibizumab, but not to pegaptanib or aflibercept. CONCLUSION:: Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin. These chemical origins may allow patients to receive pegaptanib or aflibercept despite having allergy to bevacizumab or ranibizumab.